DE60224275D1 - Moleküle und verfahren zur inhibierung der freisetzung von kim-1 - Google Patents

Moleküle und verfahren zur inhibierung der freisetzung von kim-1

Info

Publication number
DE60224275D1
DE60224275D1 DE60224275T DE60224275T DE60224275D1 DE 60224275 D1 DE60224275 D1 DE 60224275D1 DE 60224275 T DE60224275 T DE 60224275T DE 60224275 T DE60224275 T DE 60224275T DE 60224275 D1 DE60224275 D1 DE 60224275D1
Authority
DE
Germany
Prior art keywords
kim
release
inhibiting
molecules
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224275T
Other languages
English (en)
Other versions
DE60224275T2 (de
Inventor
Veronique Bailly
Joseph Bonventre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Biogen Inc
Biogen MA Inc
Original Assignee
General Hospital Corp
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Biogen Idec Inc, Biogen Idec MA Inc filed Critical General Hospital Corp
Publication of DE60224275D1 publication Critical patent/DE60224275D1/de
Application granted granted Critical
Publication of DE60224275T2 publication Critical patent/DE60224275T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60224275T 2001-06-01 2002-05-31 Moleküle und verfahren zur inhibierung der freisetzung von kim-1 Expired - Lifetime DE60224275T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29544901P 2001-06-01 2001-06-01
US295449P 2001-06-01
US29590701P 2001-06-04 2001-06-04
US295907P 2001-06-04
PCT/US2002/017402 WO2002098920A1 (en) 2001-06-01 2002-05-31 Molecules and methods for inhibiting shedding of kim-1

Publications (2)

Publication Number Publication Date
DE60224275D1 true DE60224275D1 (de) 2008-02-07
DE60224275T2 DE60224275T2 (de) 2008-12-11

Family

ID=26969139

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224275T Expired - Lifetime DE60224275T2 (de) 2001-06-01 2002-05-31 Moleküle und verfahren zur inhibierung der freisetzung von kim-1

Country Status (10)

Country Link
US (3) US7041290B2 (de)
EP (1) EP1401869B1 (de)
JP (2) JP4527394B2 (de)
AT (1) ATE382060T1 (de)
AU (1) AU2002305785B2 (de)
CA (1) CA2448427C (de)
DE (1) DE60224275T2 (de)
DK (1) DK1401869T3 (de)
NZ (1) NZ530457A (de)
WO (1) WO2002098920A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9709115A (pt) * 1996-05-24 1999-08-03 Biogen Inc Moduladores de regeneração de tecido
EP1305409B1 (de) * 2000-06-16 2009-03-11 Biogen Idec MA Inc. Renale regulatorische elemente und deren verwendung
ATE382060T1 (de) * 2001-06-01 2008-01-15 Biogen Idec Inc Moleküle und verfahren zur inhibierung der freisetzung von kim-1
US20050014687A1 (en) * 2002-03-19 2005-01-20 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2013205381B2 (en) * 2002-03-19 2016-04-14 Celldex Therapeutics, Inc. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE403440T1 (de) 2002-12-30 2008-08-15 Biogen Idec Inc Kim-1-antagonisten und verwendung zur immunsystemmodulation
WO2004084823A2 (en) * 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
AU2013242840B2 (en) * 2003-03-19 2017-01-19 Amgen Fremont Inc. Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
EP1532984A1 (de) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Antikörpern gegen CD44 zur Ausrottung der Stammzellen in akute myeloide Leukämie
WO2006094134A2 (en) * 2005-03-02 2006-09-08 Biogen Idec Ma Inc. Kim-1 antibodies for treatment of th2-mediated conditions
AU2006315580A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
EP3101031A1 (de) 2008-11-10 2016-12-07 Alexion Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von komplementassoziierten erkrankungen
US9476868B2 (en) 2009-12-23 2016-10-25 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
EP2523976B1 (de) 2010-01-11 2018-04-25 Alexion Pharmaceuticals, Inc. Biomarker für immunmodulatorische effekte bei mit antikörpern gegen cd200 behandelten patienten
CN105963694B (zh) 2010-04-30 2019-11-05 阿雷克森制药公司 抗-c5a抗体和使用所述抗体的方法
JP6150734B2 (ja) 2011-02-03 2017-06-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用
US20150110792A1 (en) * 2011-11-22 2015-04-23 Biogen Idec Ma Inc. ANTI-TIM-1 Antibodies And Uses Thereof
WO2015023836A1 (en) * 2013-08-16 2015-02-19 The Brigham And Women's Hospital, Inc. Kim-1 as a therapeutic target in conditions associated with kidney fibrosis
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
EP3568416A4 (de) * 2017-01-13 2020-07-08 Celdara Medical, LLC Chimäre antigenrezeptoren zum targeting von tim-1
IL301115A (en) 2017-04-28 2023-05-01 Acuitas Therapeutics Inc New lipid carbonyl and lipid nanoparticle formulations for delivery of nucleic acids
KR20210138569A (ko) 2019-01-11 2021-11-19 아퀴타스 테라퓨틱스 인크. 활성제의 지질 나노입자 전달을 위한 지질
IL299787A (en) 2020-07-16 2023-03-01 Acuitas Therapeutics Inc Cationic lipids for use in lipid nanoparticles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
BR9709115A (pt) * 1996-05-24 1999-08-03 Biogen Inc Moduladores de regeneração de tecido
EP1305409B1 (de) * 2000-06-16 2009-03-11 Biogen Idec MA Inc. Renale regulatorische elemente und deren verwendung
ATE382060T1 (de) * 2001-06-01 2008-01-15 Biogen Idec Inc Moleküle und verfahren zur inhibierung der freisetzung von kim-1
KR20040014997A (ko) * 2001-06-29 2004-02-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 Ｔ 세포 조절 유전자 및 그것의 사용방법
US7838220B2 (en) * 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
EP1434881A4 (de) 2001-09-17 2005-10-26 Protein Design Labs Inc Verfahren zur diagnose von krebszusammensetzungen und verfahren zum screening auf krebsmodulatoren
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) * 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
EP4091631A1 (de) * 2002-01-30 2022-11-23 The Brigham and Women's Hospital, Inc. Ein tim-3 bindemolekül zur verwendung in der behandlung einer krankheit
US20050014687A1 (en) 2002-03-19 2005-01-20 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
WO2004084823A2 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
WO2005001092A2 (en) 2003-05-20 2005-01-06 Wyeth Compositions and methods for diagnosing and treating cancers

Also Published As

Publication number Publication date
US7696321B2 (en) 2010-04-13
AU2002305785B2 (en) 2008-01-17
US20060153836A1 (en) 2006-07-13
ATE382060T1 (de) 2008-01-15
JP2010150291A (ja) 2010-07-08
EP1401869A4 (de) 2005-10-19
CA2448427A1 (en) 2002-12-12
US20080124336A1 (en) 2008-05-29
WO2002098920A1 (en) 2002-12-12
US7300652B2 (en) 2007-11-27
DK1401869T3 (da) 2008-04-28
CA2448427C (en) 2013-09-24
US20050112117A1 (en) 2005-05-26
US7041290B2 (en) 2006-05-09
EP1401869B1 (de) 2007-12-26
JP2005505256A (ja) 2005-02-24
JP4527394B2 (ja) 2010-08-18
DE60224275T2 (de) 2008-12-11
NZ530457A (en) 2007-12-21
EP1401869A1 (de) 2004-03-31

Similar Documents

Publication Publication Date Title
DE60224275D1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
DE69936409D1 (de) Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
DE60117475D1 (de) Verfahren zur Verbesserung der Fliessfähigkeit von teilchenförmigem Material
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
DE69810416D1 (de) Verfahren und Vorrichtung zur Verbesserung der Verpflanzung von Sämlingen
DE60310948D1 (de) Verfahren zur prüfung der integrität von dpfs
DE60309647D1 (de) System und Verfahren zur gesicherten Behandlung von Kontrollinformationen
SG149000A1 (en) Gag binding proteins
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE69915310D1 (de) Methoden zur behandlung der salzabhängigen hypertonie
DE60030811D1 (de) Verfahren zur Ampifizierung von RNA
DE60024705D1 (de) Reaktionsvorrichtung zur Herstellung von Alkanolamin sowie Verfahren zur Alkanolaminherstellung mit Verwendung der Vorrichtung
DE60321824D1 (de) System und verfahren zur minimierung der modulationsinstabilität
ATE397077T1 (de) Substraten und nachweise zur wirksamkeit von beta-secretase
ATE357540T1 (de) Verfahren zur bakterienunterstützten haldenauslaugung von chalkopyrit
DE50006521D1 (de) Verfahren zur aktivierung von passiviertem eisen
DE69832662D1 (de) Verfahren zur Kultur von Hepatocyten
DE50112418D1 (de) Verfahren zur sicheren Distribution von Sicherheitsmodulen
ATE232721T1 (de) Verfahren zur vermehrung der produktion und zur verbesserung der qualität von sperma
DE60017997D1 (de) Versiegelungsmaterialzusammensetzung für Karten und Verfahren zur Herstellung von Karten unter Verwendung der Zusammensetzung
DK1385993T3 (da) Fremgangsmåde til detektering og behandling af tuberøs sclerose kompleksrelaterede lidelser
DE19983191T1 (de) Verfahren zur Steigerung der Effizienz von Geschäften
ATE321748T1 (de) Verfahren zur fluormethylierung von alkoholen
DE60015718D1 (de) Sulfatierungsverfahren zur gewinnung von metallen aus sulfiderzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition